Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21

作者：Tianyang Xu, Wenwei Jiang, Lin Fan, Qiuming Gao, Guodong Li · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.20738 · 被引用次数：28 · 研究领域：Cancer-related molecular mechanisms research、Plant and Fungal Interactions Research、RNA Research and Splicing

// Tianyang Xu 1, * , Wenwei Jiang 1, * , Lin Fan 1 , Qiuming Gao 1 and Guodong Li 1 1 Department of Orthopedics, Shanghai Tenth People’s Hospital, Tong Ji University School of Medicine, Shanghai 200072, People’s Republic of China * These authors have contributed equally to this work Correspondence to: Guodong Li, email: litrue2004@163.com Keywords: osteosarcoma; Xist; proliferation; EZH2; P21 Received: April 25, 2017      Accepted: August 07, 2017      Published: September 08, 2017 ABSTRACT Recent studies show that lncRNAs involve in the initiation and progression of various cancers including osteosarcoma (OS). IncRNA Xist has been verified as an oncogene in several human cancers, and its abnormal expression was closely associated with tumor initiation and progression. Nevertheless, the role of Xist in OS remains unclear. Here, we revealed the Xist expression level was up-regulated in OS tissues and discovered that Xist knockdown significantly repressed OS cell proliferation. Additionally, mechanistic analysis revealed that Xist can repress P21 expression to regulate OS cell cycle and proliferation by binding to EZH2. Taking all into account, Xist may function in promoting OS cell proliferation and may potentially serve as a novel biomarker and therapeutic target for OS.